Department of Urology, Mayo Clinic, Rochester, Minnesota.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
J Urol. 2017 Oct;198(4):795-802. doi: 10.1016/j.juro.2017.04.016. Epub 2017 Apr 8.
Chronic kidney disease may adversely affect survival following nephrectomy. Proteinuria is increasingly used as a marker of kidney disease. However, the relationship between preoperative proteinuria and survival after nephrectomy remains incompletely characterized. We evaluated the association of preoperative proteinuria with overall and cancer specific survival using our institutional nephrectomy registry.
We identified 1,846 patients with localized clear cell renal cell carcinoma treated with curative intent (radical or partial nephrectomy) between 1995 and 2010. Patients were categorized for analysis based on preoperative proteinuria severity (mild, moderate or severe). Overall and cancer specific survival was estimated by the Kaplan-Meier method. Cox proportional hazards regression models were used to assess for variables associated with overall and cancer specific mortality.
Preoperative urine protein testing was available in 1,347 patients (73%). A total of 804 patients (60%) were classified with mild proteinuria (less than 150 mg per day), 332 (25%) were classified with moderate proteinuria (150 to 500 mg per day) and 211 (16%) were classified with severe proteinuria (greater than 500 mg per day). On multivariable analysis with mild proteinuria as the reference category the adjusted HR for all cause mortality was 1.18 (95% CI 0.95-1.48, p = 0.14) for moderate proteinuria and 1.61 (95% CI 1.26-2.07, p <0.001) for severe proteinuria. However, the proteinuria level was not associated with cancer specific survival.
Severe preoperative proteinuria is associated with worse overall survival following radical or partial nephrectomy for localized clear cell renal cell carcinoma. Preoperative proteinuria should be evaluated in patients undergoing nephrectomy and considered when estimating overall patient health status.
慢性肾脏病可能会对肾切除术后的生存率产生不利影响。蛋白尿越来越多地被用作肾脏疾病的标志物。然而,术前蛋白尿与肾切除术后生存之间的关系尚未完全明确。我们利用机构肾切除术登记处,评估术前蛋白尿与整体和癌症特异性生存之间的关系。
我们确定了 1995 年至 2010 年间接受根治性(根治性或部分性肾切除术)治疗的局限性透明细胞肾细胞癌患者 1846 例。根据术前蛋白尿严重程度(轻度、中度或重度)对患者进行分类分析。通过 Kaplan-Meier 法估计整体和癌症特异性生存率。Cox 比例风险回归模型用于评估与整体和癌症特异性死亡率相关的变量。
术前尿液蛋白检测可用于 1347 例患者(73%)。共有 804 例患者(60%)被归类为轻度蛋白尿(每天少于 150 毫克),332 例(25%)被归类为中度蛋白尿(每天 150 至 500 毫克),211 例(16%)被归类为重度蛋白尿(每天大于 500 毫克)。在多变量分析中,以轻度蛋白尿为参考类别,中度蛋白尿的全因死亡率调整后的 HR 为 1.18(95%CI 0.95-1.48,p=0.14),重度蛋白尿的 HR 为 1.61(95%CI 1.26-2.07,p<0.001)。然而,蛋白尿水平与癌症特异性生存无关。
对于局限性透明细胞肾细胞癌,术前重度蛋白尿与根治性或部分性肾切除术后整体生存率较差相关。在进行肾切除术时,应评估术前蛋白尿,并在估计患者整体健康状况时考虑。